First human exon skipping trial in US to begin in March 2010; eligible DMD participants sought
posted on October 28, 2009 - 9:39am
The first human trial in the United States of a treatment strategy known as "exon skipping" for Duchenne muscular dystrophy (DMD) is scheduled to begin in March 2010 at Nationwide Children's Hospital in Columbus, Ohio, one of five elite centers comprising MDA's DMD Clinical Research Network.
A multinational pharmaceutical company has committed to developing Prosensa's exon skipping compound for DMD
posted on October 19, 2009 - 9:00pm
On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon skipping” compound PRO051 for Duchenne muscular dystrophy (DMD).
The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.